Biocon’s arm receives USFDA’s approval for Tofacitinib Extended-Release Tablets

19 Nov 2025 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA for Tofacitinib Extended-Release Tablets. Final approval received for 11mg strength and tentative approval for 22mg strength. Tofacitinib extended-release tablets are a Janus kinase (JAK) inhibitor indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

391.45 3.20 (0.82%)
05-Dec-2025 14:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.30
Dr. Reddys Lab 1274.40
Cipla 1525.60
Zydus Lifesciences 933.90
Lupin 2101.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×